Effect of multiple‐dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin

AIM: We report on two Phase 1, open‐label, single‐arm studies assessing the effect of osimertinib on simvastatin (CYP3A substrate) and rosuvastatin (breast cancer resistance protein substrate [BCRP] substrate) exposure in patients with advanced epidermal growth factor receptor (EGFR)‐mutated non‐sma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Harvey, R. Donald, Aransay, Noemi Reguart, Isambert, Nicolas, Lee, Jong‐Seok, Arkenau, Tobias, Vansteenkiste, Johan, Dickinson, Paul A., Bui, Khanh, Weilert, Doris, So, Karen, Thomas, Karen, Vishwanathan, Karthick
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6256010/
https://ncbi.nlm.nih.gov/pubmed/30171779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13753
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados